7 Pulmonary Embolism Nursing Care Plans

What is pulmonary embolism?

Pulmonary embolism (PE) happens when a thrombus lodges in a pulmonary artery and blocks blood flow to the lung. It usually starts as a deep vein thrombosis (DVT) in the lower extremities; part of that clot breaks off and travels to the pulmonary circulation. PE is not a disease on its own. It is a complication of venous thrombosis, and it is one of the most common preventable causes of death in hospitalized patients.

When a pulmonary artery is obstructed, the lung ventilates without perfusion, and gas exchange fails. Substances released from the clot constrict vessels, raising pulmonary vascular resistance and pulmonary arterial pressure. That can drive right ventricular failure, falling cardiac output, and shock. Atrial fibrillation can also throw clots from the right atrium. Massive PE presents with hemodynamic instability; multiple small emboli can cause lung infarctions.

PE is classified as acute or chronic and central or peripheral:

• Acute. The embolus sits centrally in the vascular lumen or occludes a vessel and distends it.
• Chronic. The embolus is eccentric and contiguous with the vessel wall, reduces the arterial diameter by more than 50%, shows recanalization within the thrombus, and an arterial web is present.
• Central. Central zones include the main pulmonary artery, the left upper lobe trunk, the right middle lobe artery, and the right and left lower lobe arteries. PE is massive when it involves both pulmonary arteries or causes hemodynamic compromise.
• Peripheral. Peripheral zones include the segmental and subsegmental arteries of all lobes and the lingula.

Symptoms track with the size and location of the embolus. Classic presentation is abrupt pleuritic chest pain, shortness of breath, and hypoxia, but most patients have no obvious symptoms at presentation. Know the risk factors: hypercoagulability, vein wall damage, prolonged immobility, recent surgery, DVT, postpartum state, polycythemia, heart failure, and trauma. Treatment ranges from thrombolytics in acute cases to anticoagulation and supportive measures like oxygen and compression stockings, depending on the degree of cardiopulmonary compromise.

Nursing Care Plans & Management

Care centers on patient safety, gas exchange, complication prevention, and emotional support: monitor vital signs, give supplemental oxygen, manage pain, run DVT prevention, teach medication adherence and followup, and watch for complications.

Nursing Problem Priorities

• Minimizing risk for pulmonary embolism.
• Assessing potential for pulmonary embolism.
• Monitoring thrombolytic therapy.
• Preventing thrombus formation.

Nursing Assessment

Symptoms depend on clot size and the artery affected. Dyspnea is the most common symptom; tachypnea is the most common sign. Chest pain is often sudden and pleuritic and can mimic angina or MI. Other findings include anxiety, fever, tachycardia, cough, diaphoresis, hemoptysis, and syncope. PE can present with few symptoms or mimic other cardiopulmonary disorders; severe cases bring severe dyspnea, sudden chest pain, a rapid weak pulse, shock, syncope, and sudden death.

Assess for the following subjective and objective data:

• Confusion
• Decreased PaO2 and increased PaCO2
• Desaturation (oxygen saturation below 90%)
• Dyspnea
• Headache
• Hypercapnia
• Hypoxia
• Pale skin
• Restlessness/irritability
• Tachypnea
• Abnormal arterial blood gases (ABGs)
• Impaired chest excursion
• Tachycardia
• Use of accessory muscles

Assess for factors related to the cause of PE:

• Decreased lung perfusion from obstruction of pulmonary arterial blood flow by the embolus
• Decreased bronchial airflow from bronchoconstriction
• Increased physiological shunting from alveolar collapse after surfactant loss
• Increased alveolar dead space
• Anxiety and fear

Nursing Diagnosis

After assessment, the diagnosis names the patient's specific problems based on your clinical judgment. Diagnostic labels matter less at the bedside than the actions they drive, so use them to organize care and prioritize what the patient needs.

Nursing Goals

Goals and expected outcomes may include:

• The patient maintains adequate gas exchange: ABGs within normal range, oxygen saturation of 90% or greater, alert mentation or no further drop in level of consciousness, and baseline HR.
• The patient reports or shows resolution or absence of respiratory distress.
• The patient maintains an effective breathing pattern: relaxed breathing at normal rate and depth, no dyspnea.
• The patient verbalizes the importance of medications, signs of excessive anticoagulation, and ways to reduce bleeding risk and recurrence.
• The patient participates in the learning process.

Nursing Interventions and Actions

Here are the nursing interventions for pulmonary embolism.

1. Minimizing Pulmonary Embolism Risk

Preventing clots is frontline nursing work: promote mobility, teach leg exercises, and discourage prolonged sitting or lying. Use intermittent pneumatic compression (IPC) devices and fit inflatable sleeves correctly to boost leg blood flow. Avoid prolonged IV catheter placement to cut clot risk. These steps prevent venous stasis.

1. Monitor vital signs. Check BP, heart rate, respiratory rate, and oxygen saturation regularly. This catches hemodynamic instability and respiratory distress early, when you can still act.

2. Administer oxygen therapy. Give supplemental oxygen as prescribed to maintain oxygenation, relieve hypoxemia, and reduce the workload on the heart and lungs.

3. Assist with thrombolytic therapy. Give thrombolytics as prescribed in severe PE to dissolve clots and restore pulmonary blood flow before complications progress.

4. Support anticoagulant therapy. Administer anticoagulants such as heparin or warfarin as prescribed to prevent new clots and stop progression.

5. Promote mobility and ambulation. Encourage early mobilization as tolerated. This prevents venous stasis and new clot formation and avoids the complications of immobility.

6. Educate on medication adherence and side effects. Teach the patient and family the prescribed medications, the importance of adherence, side effects, and the need for regular blood monitoring.

7. Implement deep breathing and coughing exercises. These expand the lungs, mobilize secretions, prevent atelectasis, and lower pneumonia risk.

8. Provide emotional support and reassurance. PE is frightening. Address anxiety and fear directly to reduce stress and oxygen demand.

2. Managing Effective Gas Exchange & Oxygen Therapy

Stay alert for PE in any patient with reduced venous return. Recognizing high-risk patients and protecting gas exchange is central to management.

1. Assess skin color, nail beds, and mucous membranes for color changes. Cool, pale skin is a compensatory response to hypoxemia. As oxygenation and perfusion fail, peripheral tissues turn cyanotic. Duskiness and cyanosis in warm tissues like earlobes, lips, tongue, and buccal membranes point to systemic hypoxemia.

2. Monitor for changes in vital signs. Early hypoxia and hypercapnia raise respiratory rate, heart rate, and BP. As they worsen, BP may drop, heart rate stays rapid with dysrhythmias, and respiratory failure follows as the patient can no longer sustain a rapid respiratory rate.

3. Assess for signs of hypoxia: confusion, headache, diaphoresis, restlessness, tachycardia, pale skin. Hypoxia comes from increased dead space (ventilation without perfusion). Mechanisms include ventilation-perfusion mismatch, intrapulmonary shunts, reduced cardiac output, and intracardiac shunt through a patent foramen ovale.

4. Auscultate lung sounds, noting decreased ventilation and adventitious sounds. Crackles are common in PE and occur in fluid-filled tissues and airways or reflect cardiac decompensation. Absent breath sounds mark nonventilated areas.

5. Assess for signs of pulmonary infarction: fever, cough, bronchial breathing, hemoptysis, pleuritic pain, pleural friction rub, consolidation. A large embolus or multiple small clots can cause ischemic necrosis or infarction. These patients present with acute pleuritic chest pain, breathlessness, and hemoptysis. Normal ECG findings and no response to nitroglycerin help rule out ischemic myocardial pain.

6. Assess for calf tenderness, redness, swelling, and hardened areas. PE often arises from a DVT that was missed. Large thrombi can lodge at the bifurcation of the main pulmonary artery or the lobar branches and cause hemodynamic compromise.

7. Monitor ABGs. ABGs characteristically show hypoxemia, hypocapnia, and respiratory alkalosis. The PaO2 and the alveolar-arterial oxygen gradient support the diagnosis.

8. Monitor oxygen saturation as indicated. Pulse oximetry detects changes in oxygenation. Keep oxygen saturation at 90% or greater. Hypoxemia varies with the degree of airway obstruction, baseline cardiopulmonary function, and presence of shock.

9. Assess level of consciousness and mentation. Systemic hypoxemia shows first as restlessness and irritability, then progressively decreasing mentation. Syncope can occur and is linked to higher rates of hemodynamic instability and right ventricular dysfunction.

10. Assess activity intolerance: weakness, fatigue, vital sign changes, or increased dyspnea on exertion. This shows the patient's response to activity and their ability to participate in self-care.

11. Maintain bed rest, resuming activity gradually as tolerated. This lowers oxygen demand during acute respiratory distress. Early ambulation is preferred over bed rest when feasible.

12. Position the patient to support ventilation-perfusion matching. Upright and sitting positions optimize diaphragmatic excursion and lung perfusion. When the patient is on one side, keep the affected area nondependent. Elevate the head of the bed as tolerated for chest expansion and comfort.

13. Maintain a patent airway. Use deep breathing, coughing, and suctioning. Plugged or collapsed airways reduce functional alveoli and worsen gas exchange.

14. Help the patient manage fear and anxiety. Fear and severe anxiety tied to the inability to breathe increase oxygen consumption. Encourage the patient to express their feelings to regain a sense of control.

15. Monitor frequently and arrange for someone to stay with the patient as appropriate. This reassures the patient that changes will be caught and help is available. Give brief explanations of what is happening and what each intervention should do.

16. Ensure correct application of compression stockings. For patients with proximal DVT, elastic compression stockings are a safe, effective adjunct that limits postphlebitic syndrome. True gradient compression stockings are highly elastic and are proven in thromboembolism prophylaxis and in preventing progression of an existing clot in patients with DVT and PE.

17. Prepare the patient for a lung scan. This can reveal abnormal perfusion in ventilated areas, showing ventilation-perfusion mismatch and confirming the diagnosis and degree of obstruction.

18. Administer IV or oral fluids as indicated. Fluids reduce blood hyperviscosity that promotes thrombus formation. IV fluids can help or harm the hypotensive PE patient depending on where they sit on the Starling curve. Try a small fluid bolus cautiously, watch systolic and diastolic pressures, and stop immediately if the patient worsens.

19. Administer oxygen as indicated. Supplemental oxygen maintains oxygenation, reduces work of breathing, relieves dyspnea, and promotes comfort. Deliver enough oxygen continuously so the patient does not desaturate. Mechanical ventilation may be needed for respiratory support and a failing circulation.

20. Anticipate anticoagulant therapy, and thrombolytic therapy for massive thromboembolism. Heparin or enoxaparin (Lovenox) prevents recurrence of emboli but does not dissolve existing clots. For a massive thrombus or a hemodynamically unstable patient, thrombolytics (alteplase or reteplase [Retavase]) lyse the clot. Current recommendation is anticoagulation for at least 3 months, reevaluated at that point.

21. Assist with chest physiotherapy: postural drainage and percussion of nonaffected areas, blow bottles, and incentive spirometry. This deepens respiratory effort and drains secretions from lung segments into bronchi for removal by coughing or suctioning.

22. Assist with surgical interventions as indicated. Vena caval ligation or an intracaval umbrella can help patients with recurrent emboli despite adequate anticoagulation. Catheter embolectomy and fragmentation or surgical embolectomy is reasonable for massive PE when fibrinolysis is contraindicated or the patient stays unstable after it.

3. Maintaining Patent Airway Clearance and Effective Breathing Pattern

Clearing the airway prevents secretion buildup, protects oxygenation, and lowers respiratory complications. Catch breathing abnormalities early so you can intervene before the patient decompensates.

1. Assess the patient's anxiety level. PE is sudden and frightening and can produce rapid, shallow respirations and increased dyspnea, which can signal worsening hypoxemia. Young adults with VTE often carry distress from uncertainty about long-term health and fear of recurrence, and PE patients show higher depression and anxiety scores.

2. Assess respiratory rate, rhythm, and depth, plus any increased work of breathing: shortness of breath and accessory muscle use. Rate and rhythm changes are early signs of impending respiratory distress. Tachypnea is typical, and rapid shallow breathing results from hypoxia. Hypoventilation (a slowing rate) without improvement signals respiratory failure. Frank exertional dyspnea suggests rising pulmonary arterial pressure.

3. Assess pain characteristics, especially with the respiratory cycle. Pain is usually sharp or stabbing and worsens with deep breathing and coughing, causing shallow respirations that impair gas exchange. Pleuritic chest pain is worrisome and is reported in as many as 84% of PE patients; its presence suggests a more peripheral, smaller embolus.

4. Monitor ABGs. ABGs typically show hypoxemia and respiratory alkalosis from blowing off carbon dioxide. Widened alveolar-arterial oxygen gradients, respiratory alkalosis, and hypocapnia are common.

5. Monitor D-dimer results as indicated. D-dimer rises in plasma during any acute thrombotic process from simultaneous activation of coagulation and fibrinolysis. A negative ELISA D-dimer plus low clinical probability excludes PE without further testing in about 30% of suspected patients.

6. Monitor vital signs continuously. Increased respirations, tachycardia, or bradycardia suggest hypoxia. If a PE patient with tachycardia develops sudden bradycardia or a new broad complex tachycardia, look for right ventricular strain and impending shock. Suspect PE in anyone with hypotension and jugular vein distention once MI, pericardial tamponade, and tension pneumothorax are ruled out.

7. Provide reassurance and stay with the patient during acute respiratory distress. A trusted presence helps during anxiety. Distressing symptoms plus a PE diagnosis can leave patients feeling they narrowly escaped death.

8. Position the patient sitting up and reposition every 2 hours. If not contraindicated, sitting allows good lung excursion and chest expansion. Repositioning and elevating the head of the bed aids ventilation and secretion drainage.

9. Encourage deep breathing and coughing. Suction as indicated. Coughing is the most productive way to clear secretions. Suction when the patient cannot clear secretions by coughing. These keep airways open.

10. Reinforce splinting the chest with pillows during deep breathing or coughing. This reduces pleuritic chest pain, promotes lung expansion, and improves cough effort.

11. Instruct and assist with incentive spirometry. It maximizes lung inflation, reduces atelectasis, and prevents complications. It is cost-effective and reduces dyspnea and improves quality of life.

12. Prepare the patient for diagnostic studies: chest X-ray, CT scan, ventilation-perfusion scan, and pulmonary arteriogram. Chest X-ray is readily available in acute care and is usually normal or shows nonspecific findings like atelectasis or effusion; it helps rule out other causes of acute dyspnea. With high suspicion of PE, add CT and other scans. Multidetector CT pulmonary angiography (CTPA) is the diagnostic modality of choice.

13. Administer oxygen as indicated. Supplemental oxygen maintains oxygenation, reduces work of breathing, relieves dyspnea, and promotes comfort. Deliver enough continuously so the patient does not desaturate. Oxygen is indicated when saturation is <90%.

14. Anticipate intubation and mechanical ventilation. Intubation and positive-pressure ventilation stabilize breathing and prevent decompensation. Use mechanical ventilation in unstable patients, but watch for its adverse hemodynamic effects.

4. Managing Bleeding Risk & Thrombolytic Therapy

Balance effective anticoagulation against bleeding risk based on the patient's characteristics, comorbidities, and the specific regimen.

1. Assess for a history of high bleeding risk: liver disease, kidney disease, severe hypertension, cavitary tuberculosis, bacterial endocarditis, and heparin-induced thrombocytopenia. Anticoagulation is the hallmark treatment for PE, so assess prior bleeding or anticoagulant experience before treatment. Ask about underlying conditions that change the course under anticoagulant toxicity, including alcohol use and hepatic disease.

2. Assess for signs of bleeding: bleeding from catheter sites or mucous membranes, decreased hematocrit and hemoglobin, GI bleeding, genitourinary bleeding, hematoma, petechiae, purpura, and respiratory tract bleeding. Early recognition lets you give the right antidote fast. Chronic overdose toxicity presents with an elevated PT/INR at or near maximum. In naive patients, the PT/INR does not rise for 12 hours post-ingestion and may keep rising for hours from ongoing absorption, so catch early signs.

3. Monitor vital signs and compare to readings before medication. BP and pulse changes roughly estimate bleeding. A BP less than 90 mm Hg and a pulse greater than 110 suggest a 25% volume decrease, roughly 1,000 mL. Postural hypotension reflects falling circulating volume.

4. Monitor platelets in patients with heparin-induced thrombocytopenia. Severe platelet drops occur with heparin, especially unfractionated heparin, and are known as heparin-induced thrombocytopenia (HIT). HIT is less common with low-molecular-weight heparin. Suspect HIT when the platelet count falls below 100,000/µL or to less than 50% of baseline, generally after 5 to 15 days of therapy. Check platelets every 2 or 3 days from day 4 to day 14, or until heparin is stopped.

5. Monitor coagulation tests: INR, PT, aPTT, hemoglobin, and hematocrit. Notify the provider immediately for values outside the designated range. Monitor anticoagulation closely to reduce bleeding. The test depends on the drug. The anticoagulant effect is best quantified by baseline and daily PT and INR, which may not be elevated until 1 to 2 days post-ingestion. A normal PT 48 to 72 hours after ingestion rules out significant ingestion.

6. Monitor the IV dosage and delivery system (tubing or pump). IV anticoagulation runs through an electronic infusion pump to reduce over- or under-coagulation. For IV unfractionated heparin, give an initial bolus of 80 U/kg or 5000 U followed by an infusion of 18 U/kg/hour or 1300 U/hour, aiming to reach and hold an aPTT corresponding to therapeutic heparin levels.

7. Administer anticoagulant therapy as prescribed: bolus and continuous IV heparin, subcutaneous low-molecular-weight heparin, or oral warfarin (Coumadin). Anticoagulants prevent further thrombus formation. Non-heparin agents exist for patients who cannot tolerate heparin. Current guidelines favor LMWH over IV and subcutaneous unfractionated heparin for acute PE because of greater bioavailability, subcutaneous dosing, and longer duration.

8. If the patient is HIPA positive, stop all heparin products and consult hematology. Heparin is contraindicated in the HIPA-positive patient. In HIT with or without thrombosis, lepirudin, argatroban, or danaparoid is preferred over continued heparin, LMWH, or a vitamin K antagonist.

9. Act if bleeding occurs on heparin. Stop all heparin products. For life-threatening bleeding from a vitamin K antagonist (VKA), rapid reversal and replacement of clotting factors is the priority: give vitamin K 10 mg IV plus prothrombin complex concentrate or fresh frozen plasma for a sustained INR reduction. Supportive measures and clotting factor infusion can reverse DOAC bleeding.

10. Provide stool softeners as indicated. They prevent straining, which raises intra-abdominal pressure and the risk of bleeding hemorrhoidal varices, especially with hepatic problems.

11. Convert from IV to oral anticoagulation after the appropriate length of therapy. Monitor INR, PT, and aPTT. Warfarin's onset is 2 to 3 days, so overlap the medications to ensure adequate INR before stopping heparin. Continue parenteral anticoagulation and warfarin together for at least 5 days and until the INR is 2.0. The therapeutic range for VTE is an INR of 2 to 3, which markedly reduces bleeding risk without losing effectiveness.

12. Administer thrombolytic therapy as prescribed. Lytic agents are indicated for massive PE with hemodynamic compromise. Know the contraindications: recent surgery, recent organ biopsy, pregnancy, recent stroke, and recent or active internal bleeding. Do not delay thrombolysis in acute PE with hypotension (systolic BP <90 mm Hg) because irreversible cardiogenic shock can develop. Thrombolysis is not recommended for most acute PE without hypotension.

13. Institute precautionary measures for thrombolytic therapy per protocol. Follow institutional policy. To reduce bleeding: use only compressible vessels for IV sites; compress IV sites at least 10 minutes and arterial sites 30 minutes; limit physical manipulation; give gentle oral care; avoid IM injections; draw all labs through an existing arterial line or venous heparin-lock line; and send a type and crossmatch.

14. Avoid giving vitamin K as prophylaxis. Do not give vitamin K prophylactically; it is not needed in most patients and masks the onset of anticoagulant effects in those who need prolonged treatment and followup. If PT is elevated, vitamin K is appropriate.

15. Administer blood and blood products for active bleeding. Treat active serious bleeding with four-factor prothrombin complex concentrate (PCC) when available. PCC reverses coagulopathy faster than FFP and needs no thawing or blood typing, though it is costly. Recombinant factor VIIa can rapidly lower INR from warfarin toxicity and may be considered if PCC is unavailable.

16. Administer antidotes if available and indicated. Activated charcoal can limit systemic absorption if the patient took DOACs. Vitamin K1 (phytomenadione) overcomes the competitive block from warfarin and related anticoagulants and is used only when anticoagulation is evident.

5. Monitoring Diagnostic and Laboratory Procedures

Track these studies to confirm PE, gauge its extent, and monitor the response to treatment.

1. Computed tomography pulmonary angiography (CTPA). Uses contrast dye and CT to visualize the pulmonary arteries and detect clots.

2. Ventilation-perfusion (V/Q) scan. Uses injected radioactive material and contrast to assess airflow and blood flow, identifying ventilation-perfusion mismatch that points to PE.

3. D-dimer test. Measures D-dimer, a fragment elevated when clots break down. A negative result helps rule out PE; a positive result needs imaging to confirm.

4. Chest X-ray. Not definitive for PE, but evaluates the lungs, heart, and other structures, excludes other conditions, and may show an enlarged right ventricle or abnormal pulmonary artery shape.

5. Echocardiography. Visualizes cardiac structure and function and can show right ventricular strain or dysfunction from PE.

6. Blood gas analysis. Measures arterial oxygen and carbon dioxide and gauges the severity of respiratory compromise.

7. Electrocardiogram (ECG). Records cardiac electrical activity and can show right bundle branch block or right ventricular strain.

8. Lower extremity venous Doppler ultrasonography. Noninvasive test of blood flow in the deep leg veins that identifies DVT, which often precedes PE.

6. Administering Medications and Pharmacological Support

Drug choice depends on severity, patient characteristics, and contraindications.

1. Anticoagulants (heparin, warfarin, direct oral anticoagulants). The mainstay of treatment. They prevent new clots and extension of existing ones. Heparin is usually started first, then transitioned to oral warfarin or a DOAC for long-term management.

2. Thrombolytics (alteplase, reteplase). Used in severe PE to dissolve clots rapidly, reserved for significant hemodynamic instability or high risk of poor outcomes.

3. NSAIDs. Ibuprofen or naproxen can relieve pain and inflammation associated with PE.

4. Analgesics. Opioids or non-opioid analgesics (acetaminophen) relieve chest pain and discomfort and support better breathing.

5. Oxygen therapy. Given for hypoxemia to maintain oxygenation, relieve shortness of breath, and support respiratory function.

6. Prophylactic medications. Low-molecular-weight heparin or fondaparinux can prevent clot formation in high-risk situations like surgery or prolonged immobility.

7. Providing Patient Education & Health Teachings

Teaching helps patients participate in care, make informed decisions, and change habits to lower recurrence risk. Focus on understanding the condition, its causes, and risk factors.

1. Assess the patient's knowledge of PE: severity, prognosis, risk factors, and therapy. PE is often a first-time event with no prior experience to draw on, so this is your starting point. In survivors, prompt diagnosis, therapy, and patient knowledge prevent recurrence and death.

2. Assess knowledge of anticoagulant therapy and the complications of nonadherence. Many prescribed VTE prophylaxis doses go unadministered, most often from patient refusal or poor nurse-patient communication. Missing even one dose is linked to VTE events, so adherence teaching is essential.

3. Explain the cause, common risk factors, and effects of PE on the body. Preventing thrombus formation is ongoing, and an informed patient avoids risk factors. Because signs and symptoms are nonspecific, patients with unexplained dyspnea, tachypnea, chest pain, or PE risk factors need diagnostic testing until PE is confirmed or ruled out.

4. Explain activity restrictions and the balance between activity and rest. Set up appropriate exercise and activity programs. Rest lowers oxygen and nutrient demand and reduces fragmentation of thrombosis. Balancing rest and activity prevents exhaustion. An exercise program builds collateral circulation, improves venous return, and prevents recurrence.

5. Problem-solve predisposing factors: jobs requiring prolonged standing or sitting, restrictive clothing, oral contraceptives, obesity, prolonged immobility, and dehydration. This involves the patient in lifestyle changes. Immobility causes venous stasis as clotting factors and fibrin accumulate. Estrogen-containing birth control pills raise VTE occurrence in healthy women.

6. Tell the patient to avoid sitting cross-legged for long periods. Sit with feet on the floor instead of crossing the legs to avoid pressure on the popliteal space that can dislodge a thrombus.

7. Review the purpose and demonstrate correct application and removal of anti-embolic hose. Understanding improves cooperation and prevents misuse. Stockings with 30 to 40 mm Hg of pressure at the ankle, worn for 2 years after diagnosis, reduce the risk of postphlebitic syndrome. The common white anti-embolic stockings ("Ted hose") produce a maximum compression of 18 mm Hg.

8. Instruct in meticulous skin care of the lower extremities. Chronic venous congestion and postphlebitic syndrome can develop with severe vascular involvement and recurrent DVT, raising the risk of stasis ulcers. Prevent or promptly treat skin breaks and report ulcers or color changes.

9. Explain the need for routine lab testing on oral anticoagulation. Ongoing assessment prevents both recurrent clots and active bleeding. The therapeutic dose range is narrow and complications can be fatal, so close supervision matters. Prothrombin time (PT) should be measured regularly; the goal is an INR of 2 to 3.

10. Instruct about medications: actions, dosages, and side effects. Patients may need anticoagulation for weeks to months depending on risk. Long-term anticoagulation is essential after an initial DVT or PE. The optimal duration is debated, but at least 6 months is associated with a significant reduction in recurrence and a net benefit.

11. Discuss a medical alert bracelet or other identification. It alerts emergency providers to the patient's anticoagulation history and the need for prophylaxis before and after procedures or events that raise VTE risk.

12. Discuss drug, herb, alcohol, and food interactions with anticoagulants. Stress that significant diet changes and all over-the-counter medications and complementary therapies be discussed with the provider before starting. Foods, supplements, and herbs can change DOAC plasma concentrations. Patients on anticoagulants should avoid St. John's wort and limit vitamin K-rich foods like lettuce, broccoli, spinach, and green peas, which can reduce the effect of vitamin K antagonists (VKA). Taking dabigatran while fasting can increase GI adverse effects and lead to discontinuation. Insoluble and soluble fiber and cellulose may lower the bioavailability of apixaban, edoxaban, and dabigatran.

13. Educate about signs of anticoagulant toxicity: severe nosebleeds, black stools, blood in urine or stool, joint swelling or pain, hemoptysis, and severe headache. Patients may need to self-manage, and early recognition speeds treatment. Ask about any abnormal bleeding to guide treatment.

14. Identify safety precautions to prevent bleeding. Use a soft toothbrush, an electric razor, and gloves for gardening; avoid sharp objects including toothpicks, walking barefoot, rough sports, and forceful nose blowing. These reduce traumatic injury that triggers bleeding or clot formation.

15. If the patient is heparin-induced platelet aggregation (HIPA) positive, stress avoiding heparin. Heparin can trigger anti-heparin antibodies. Treatment for HIT is to stop all heparin products, including catheter flushes and heparin-coated catheters, and start a non-heparin anticoagulant even without clinically apparent thrombosis.

16. Explain the need for a vena cava filter if clotting is a chronic problem. In high-risk patients, the filter traps a thrombus migrating from a leg DVT. Patients with acute PE should not routinely get a filter in addition to anticoagulants. After IVC filter placement, resume anticoagulation once contraindications or active bleeding have resolved.

Frequently Asked Questions

What is a pulmonary embolism? A pulmonary embolism happens when a thrombus lodges in a pulmonary artery and blocks blood flow to the lung. It usually starts as a deep vein thrombosis in the legs, and part of that clot breaks off and travels to the pulmonary circulation. PE is a complication of venous thrombosis and one of the most common preventable causes of death in hospitalized patients.

What are the most common symptom and sign? Dyspnea is the most common symptom and tachypnea is the most common sign. The classic presentation is abrupt pleuritic chest pain, shortness of breath, and hypoxia, but many patients have few obvious symptoms at presentation.

How is PE diagnosed? Multidetector CT pulmonary angiography (CTPA) is the diagnostic modality of choice. A negative ELISA D-dimer plus a low clinical probability can exclude PE without further testing. Ventilation-perfusion scanning, echocardiography, and lower-extremity venous Doppler add information about the clot and its source.

How is PE treated? Anticoagulation is the cornerstone. Heparin or low-molecular-weight heparin is usually started first, then transitioned to warfarin or a direct oral anticoagulant. Thrombolytics are reserved for massive PE with hemodynamic instability, alongside oxygen and supportive care.

How long does anticoagulation last? The current recommendation is anticoagulation for at least 3 months, reassessed at that point based on the patient's risk of recurrence and bleeding.

How can nurses help prevent PE? Promote early mobility and leg exercises, discourage prolonged sitting or lying, fit intermittent pneumatic compression devices and graduated compression stockings correctly, and avoid prolonged IV catheter placement. These steps prevent venous stasis.